TY - JOUR
T1 - Pick’s disease
T2 - clinicopathologic characterization of 21 cases
AU - Choudhury, Parichita
AU - Scharf, Eugene L.
AU - Paolini, Michael A.
AU - Graff-Radford, Jonathan
AU - Alden, Eva C.
AU - Machulda, Mary M.
AU - Jones, David T.
AU - Fields, Julie A.
AU - Murray, Melissa E.
AU - Graff-Radford, Neill R.
AU - Constantopoulos, Eleni
AU - Reichard, Ross R.
AU - Knopman, David S.
AU - Duffy, Joseph R.
AU - Dickson, Dennis W.
AU - Parisi, Joseph E.
AU - Josephs, Keith A.
AU - Petersen, Ronald C.
AU - Boeve, Bradley F.
N1 - Funding Information:
Drs. Choudhury, Scharf, Jones, Duffy, Reichard, Alden, Paolini, Murray, Dickson and Parisi have no conflicts of interests or disclosures. Dr. J Graff-Radford receives research support from National Institute of Health. Dr. Duffy has no conflicts of interest. Ms. Constantopolous has no disclosures. Dr. Fields has no conflicts of interests. She receives research support from NIH. Dr. Machulda received research support from National Institute of Health and National Institute of Deafness and Other Communication Disorders. Dr. Josephs has no conflicts of interest. He receives research support from the National Institute of Health. Dr. Knopman served on a Data Safety Monitoring Board for the DIAN study. He serves on a Data Safety monitoring Board for a tau therapeutic for Biogen, but receives no personal compensation. He is an investigator in clinical trials sponsored by Biogen, Lilly Pharmaceuticals and the University of Southern California. He serves as a consultant for Samus Therapeutics, Third Rock and Alzeca Biosciences, but receives no personal compensation. He receives research support from the NIH. Dr. Petersen has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Roche, Inc. Merck, Inc. Genentech, Inc. Biogen, Inc. Eisai, Inc. GE Healthcare. Dr. Petersen has received personal compensation in an editorial capacity for UpToDate. Dr. N Graff-Radford has received research support from Eli Lilly, Novartis, Biogen, and AbbVie. Dr. Boeve serves as an investigator for clinical trials sponsored by Biogen, Alector, and EIP Pharma. He receives royalties from the publication of a book entitled Behavioral Neurology of Dementia (Cambridge Medicine, 2009, 2017). He serves on the Scientific Advisory Board of the Tau Consortium. He receives research support from the NIH, the Mayo Clinic Dorothy and Harry T. Mangurian Jr. Lewy Body Dementia Program, the Little Family Foundation, and the Turner Family Foundation.
Funding Information:
This study was funded by Alzheimer Disease Research Center (ADRC) (Grant Numbers: P30 AG016574 and P50 AG062677).
Publisher Copyright:
© 2020, Springer-Verlag GmbH Germany, part of Springer Nature.
PY - 2020/9/1
Y1 - 2020/9/1
N2 - Background: Pick’s disease (PiD) is a unique subtype of frontotemporal lobar degeneration characterized pathologically by aggregates of 3-Repeat tau. Few studies have examined the clinical variability and disease progression in PiD. We describe the clinical features, neuropsychological profiles and coexistent pathologies in 21 cases of autopsy-confirmed PiD. Methods: This study was a retrospective analysis of patients with Pick’s disease evaluated at Mayo Clinic, Rochester or Jacksonville (1995–2018), and identified through an existing database. Results: Twenty-one cases with sufficient clinical data were identified. Behavioral variant FTD (bvFTD; 12/21) was the most common phenotype, followed by primary progressive aphasia (PPA; 7/21), corticobasal syndrome (CBS; 1/21) and amnestic dementia (1/21). Median age at disease onset was 54 years, with PPA cases (median = 52 years) presenting earlier than bvFTD (median = 59). Median disease duration (onset–death) overall was 10 years and did not differ significantly between bvFTD (median = 9.5 years) and PPA (median = 13). Age at death was not significantly different in PPA (median = 66) compared to bvFTD (median = 68.5). A third of the cases (n = 7/21) demonstrated pure PiD pathology, while the remainder showed co-existent other pathologies including Alzheimer’s type (n = 6), cerebral amyloid angiopathy (n = 3), combined Alzheimer’s and amyloid angiopathy (n = 4), and Lewy body disease (n = 1). Conclusions: Our study shows that bvFTD and PPA are the most common clinical phenotypes associated with PiD, although rare presentations such as CBS were also seen. Coexisting non-Pick’s pathology was also present in many cases. Our study highlights the clinical and pathologic heterogeneity in PiD.
AB - Background: Pick’s disease (PiD) is a unique subtype of frontotemporal lobar degeneration characterized pathologically by aggregates of 3-Repeat tau. Few studies have examined the clinical variability and disease progression in PiD. We describe the clinical features, neuropsychological profiles and coexistent pathologies in 21 cases of autopsy-confirmed PiD. Methods: This study was a retrospective analysis of patients with Pick’s disease evaluated at Mayo Clinic, Rochester or Jacksonville (1995–2018), and identified through an existing database. Results: Twenty-one cases with sufficient clinical data were identified. Behavioral variant FTD (bvFTD; 12/21) was the most common phenotype, followed by primary progressive aphasia (PPA; 7/21), corticobasal syndrome (CBS; 1/21) and amnestic dementia (1/21). Median age at disease onset was 54 years, with PPA cases (median = 52 years) presenting earlier than bvFTD (median = 59). Median disease duration (onset–death) overall was 10 years and did not differ significantly between bvFTD (median = 9.5 years) and PPA (median = 13). Age at death was not significantly different in PPA (median = 66) compared to bvFTD (median = 68.5). A third of the cases (n = 7/21) demonstrated pure PiD pathology, while the remainder showed co-existent other pathologies including Alzheimer’s type (n = 6), cerebral amyloid angiopathy (n = 3), combined Alzheimer’s and amyloid angiopathy (n = 4), and Lewy body disease (n = 1). Conclusions: Our study shows that bvFTD and PPA are the most common clinical phenotypes associated with PiD, although rare presentations such as CBS were also seen. Coexisting non-Pick’s pathology was also present in many cases. Our study highlights the clinical and pathologic heterogeneity in PiD.
KW - Frontotemporal dementia
KW - Pick’s disease
KW - Primary progressive aphasia
UR - http://www.scopus.com/inward/record.url?scp=85084983161&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85084983161&partnerID=8YFLogxK
U2 - 10.1007/s00415-020-09927-9
DO - 10.1007/s00415-020-09927-9
M3 - Article
C2 - 32440921
AN - SCOPUS:85084983161
SN - 0340-5354
VL - 267
SP - 2697
EP - 2704
JO - Deutsche Zeitschrift fur Nervenheilkunde
JF - Deutsche Zeitschrift fur Nervenheilkunde
IS - 9
ER -